Navigating The Depths Of Preclinical Oncology To Guide Your Cancer Drug Discovery
Embarking on a drug discovery journey can feel like exploring uncharted territory. But with TD2 as your trusted preclinical oncology partner, you can be confident that you’ll find your way to the clinic. Our team of experienced researchers has extensive knowledge in solid and hematologic tumors, immuno-oncology, and adoptive cell therapy. We provide a consultative approach to ensure the best results and continuity with your future clinical and regulatory strategy. With over 600 first-in-human studies under our belt, we have the specialized oncology knowledge to design and execute your preclinical program to support your clinical and regulatory goals. Trust TD2 for optimal study design and rapid study initiation.
At TD2, we know that time is of the essence when it comes to drug discovery. That’s why we continue to expand our preclinical service offerings. New services include humanized immune checkpoint inhibitor mouse models, diet-induced obesity mouse models, and metabolomic analysis services. These models are designed to provide you with the data you need to make informed decisions about your program and move your treatments to the clinic as quickly as possible. With TD2, you’ll have a partner that is committed to your success every step of the way.
Comprehensive preclinical services.
Personalized, Expert Support
- 300+ established mouse models
- 400+ cancer cell lines
- Precision dosing – Tecan D300 digital dispenser
- Combination interactions with immune effector cells
- Synergy studies
- Non-GLP safety and tolerability
- Metabolomics and Proteomics Analysis
- Bioanalytical and DMPK capabilities
- Biomarker screening
- Optical imaging